Monoclonal antibody · Antagonist of P-selectin (SELP) · developed by Novartis Pharms
Crizanlizumab is a humanized IgG2 kappa monoclonal antibody that binds P-selectin on activated endothelium and platelets, blocking its interaction with PSGL-1 and other ligands. It can also dissociate preformed P-selectin/PSGL-1 complexes, which reduces adhesion between endothelial cells, platelets, red blood cells and leukocytes. It is studied in sickle cell disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.
Sickle Cell Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →